A detailed history of Mv Capital Management, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Mv Capital Management, Inc. holds 87 shares of REGN stock, worth $64,206. This represents 0.01% of its overall portfolio holdings.

Number of Shares
87
Previous 86 1.16%
Holding current value
$64,206
Previous $90,000 1.11%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$1024.09 - $1201.76 $1,024 - $1,201
1 Added 1.16%
87 $91,000
Q2 2024

Aug 01, 2024

BUY
$883.2 - $1071.19 $6,182 - $7,498
7 Added 8.86%
86 $90,000
Q1 2024

Apr 18, 2024

SELL
$902.69 - $993.35 $3,610 - $3,973
-4 Reduced 4.82%
79 $76,000
Q4 2023

Jan 29, 2024

BUY
$775.18 - $881.7 $6,201 - $7,053
8 Added 10.67%
83 $72,000
Q3 2023

Nov 07, 2023

BUY
$692.45 - $844.37 $3,462 - $4,221
5 Added 7.14%
75 $61,000
Q1 2023

Apr 26, 2023

BUY
$680.49 - $826.97 $5,443 - $6,615
8 Added 12.9%
70 $57,000
Q4 2022

Jan 27, 2023

BUY
$705.89 - $766.39 $2,117 - $2,299
3 Added 5.08%
62 $0
Q3 2022

Oct 24, 2022

BUY
$573.97 - $724.32 $4,017 - $5,070
7 Added 13.46%
59 $41,000
Q2 2022

Jul 19, 2022

BUY
$548.35 - $738.84 $8,773 - $11,821
16 Added 44.44%
52 $31,000
Q1 2022

May 09, 2022

BUY
$595.12 - $698.43 $2,380 - $2,793
4 Added 12.5%
36 $25,000
Q4 2021

Feb 02, 2022

SELL
$543.48 - $670.97 $1,086 - $1,341
-2 Reduced 5.88%
32 $20,000
Q3 2021

Nov 12, 2021

BUY
$574.03 - $680.96 $8,036 - $9,533
14 Added 70.0%
34 $21,000
Q2 2021

Aug 03, 2021

BUY
$472.8 - $558.54 $8,037 - $9,495
17 Added 566.67%
20 $11,000
Q1 2021

May 12, 2021

BUY
$446.73 - $548.2 $1,340 - $1,644
3 New
3 $1,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Mv Capital Management, Inc. Portfolio

Follow Mv Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mv Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mv Capital Management, Inc. with notifications on news.